Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Ana Gimenez-Capitan"'
Autor:
Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Danijela Koppers-Lalic
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 5, p 4881 (2023)
Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity necessary to rea
Externí odkaz:
https://doaj.org/article/508b8d699bbb4150bd895b6180ff88bf
Autor:
Jillian W. P. Bracht, Ana Gimenez-Capitan, Chung-Ying Huang, Nicolas Potie, Carlos Pedraz-Valdunciel, Sarah Warren, Rafael Rosell, Miguel A. Molina-Vila
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Extracellular vesicles (EVs) are double-layered phospholipid membrane vesicles that are released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform
Externí odkaz:
https://doaj.org/article/b409b0d38d0943b78e064bba707fd0fb
Autor:
Niki Karachaliou, Maria Gonzalez-Cao, Guillermo Crespo, Ana Drozdowskyj, Erika Aldeguer, Ana Gimenez-Capitan, Cristina Teixido, Miguel Angel Molina-Vila, Santiago Viteri, Maria De Los Llanos Gil, Salvador Martin Algarra, Elisabeth Perez-Ruiz, Ivan Marquez-Rodas, Delvys Rodriguez-Abreu, Remedios Blanco, Teresa Puertolas, Maria Angeles Royo, Rafael Rosell
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression of IFNG, the gene encoding IFN-γ, is associated with clinical response to
Externí odkaz:
https://doaj.org/article/8ac2c8fef28b486789e2a6c0357c1a10
Autor:
Mireia Margeli, Beatriz Cirauqui, Eva Castella, Gustavo Tapia, Carlota Costa, Ana Gimenez-Capitan, Agusti Barnadas, Maria Sanchez Ronco, Susana Benlloch, Miquel Taron, Rafael Rosell
Publikováno v:
PLoS ONE, Vol 5, Iss 3, p e9499 (2010)
BACKGROUND: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadi
Externí odkaz:
https://doaj.org/article/71e350bcc5754acfae272dd603d1119d
Autor:
Miquel Taron, Charles L Sawyers, Trever G Bivona, Jose Javier Sanchez, Susana Benlloch, Aurelio Ariza, Jose Luis Mate, Maria Sanchez-Ronco, Jose Miguel Sanchez, Itziar de Aguirre, Cristina Queralt, Bartomeu Massuti, Ruth Porta, Enric Carcereny, Santiago Viteri, Margarita Majem, Noemi Reguart, Rosario Garcia-Campelo, Amelia Insa, Manuel Cobo, Mariano Provencio, Dolores Isla, Felipe Cardenal, Pedro Mendez, Teresa Moran, Clara Mayo, Jordi Bertran-Alamillo, Ana Gimenez-Capitan, Sara Simonetti, Carlota Costa, Miguel Angel Molina, Rafael Rosell
Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69cd84e97790f5009bb9f3de55f4f9ee
https://doi.org/10.1158/1078-0432.c.6520164.v1
https://doi.org/10.1158/1078-0432.c.6520164.v1
Autor:
Miquel Taron, Charles L Sawyers, Trever G Bivona, Jose Javier Sanchez, Susana Benlloch, Aurelio Ariza, Jose Luis Mate, Maria Sanchez-Ronco, Jose Miguel Sanchez, Itziar de Aguirre, Cristina Queralt, Bartomeu Massuti, Ruth Porta, Enric Carcereny, Santiago Viteri, Margarita Majem, Noemi Reguart, Rosario Garcia-Campelo, Amelia Insa, Manuel Cobo, Mariano Provencio, Dolores Isla, Felipe Cardenal, Pedro Mendez, Teresa Moran, Clara Mayo, Jordi Bertran-Alamillo, Ana Gimenez-Capitan, Sara Simonetti, Carlota Costa, Miguel Angel Molina, Rafael Rosell
Supplementary Figures S1-S3; Supplementary Tables S1-S14.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3105b94bf9013d178ef6007ed46f8c
https://doi.org/10.1158/1078-0432.22444437
https://doi.org/10.1158/1078-0432.22444437
Autor:
Silvia García-Roman, Mónica Garzón-Ibáñez, Jordi Bertrán-Alamillo, Núria Jordana-Ariza, Ana Giménez-Capitán, Beatriz García-Peláez, Marta Vives-Usano, Jordi Codony-Servat, Erik d'Hondt, Rafael Rosell, Miguel Ángel Molina-Vila
Publikováno v:
Translational Oncology, Vol 40, Iss , Pp 101878- (2024)
Background: The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies, such as cetuximab or pani
Externí odkaz:
https://doaj.org/article/fc3b1c5adf764070ae7e5f5cd5f1ee1a
Autor:
Ana Giménez‐Capitán, Estela Sánchez‐Herrero, Lucía Robado de Lope, Andrés Aguilar‐Hernández, Ivana Sullivan, Virginia Calvo, Irene Moya‐Horno, Santiago Viteri, Carlos Cabrera, Cristina Aguado, Noelia Armiger, Joselyn Valarezo, Clara Mayo‐de‐las‐Casas, Noemí Reguart, Rafael Rosell, Mariano Provencio, Atocha Romero, Miguel A. Molina‐Vila
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1884-1897 (2023)
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material
Externí odkaz:
https://doaj.org/article/895f32ea609d4f95922800c025292cd9
Autor:
Cristina Aguado, Irene Moya, Andrés Aguilar, Ana Gimenez Capitan, Rafael Rosell, Noemi Reguart, Nuria Viñolas, Santiago Viteri, Ruth Román, Sonia Rodríguez, Elba Marin, Cristina Teixidó, Roxana Reyes, Miguel Angel Molina-Vila
Publikováno v:
Cancer Research. 81:469-469
Background: Fusion involving anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET) or ROSproto-oncogene 1, receptor tyrosine kinase (ROS1), neurotrophic receptor tyrosine kinase 1 (NTRK1)and neuregulin 1 (NRG1) are present in lung cancer (LC) an
Autor:
Richard Boykind, Carlos González Pedraz, Clara Mayo-de-las-Casas, Jillian Wilhelmina Paulina Bracht, Carlos Cabrera-Gálvez, A. Aguilar-Hernández, Pablo Rubinstein, Alejandro Martinez-Bueno, Nicolas Potie, Maria Gonzalez-Cao, Miguel Ángel Molina-Vilaa, Chung-Ying Huang, Ana Gimenez Capitan, Rafael Rosell, Santiago Viteri, Sarah H. Warren, Joselyn Valarezo
Publikováno v:
Cancer Research. 81:2606-2606
Background: 80% of non-small cell lung cancer (NSCLC) cases are diagnosed at stages IIIB-IV and have a dismal prognosis with a median life expectancy that does not exceed 2 years. In contrast, patients diagnosed at early and locally advanced stages (